Attentin (dexamphetamine) is a prescription drug, 5 mg, 10 mg and 20 mg tablets.
Indication: Dexamphetamine is intended for children and adolescents aged 6 to 17 as part of a comprehensive
treatment program for ADHD (Attention Deficit Hyperactivity Disorder) when responding to earlier
treatment with methylphenidate is considered to be clinically inadequate. Treatment should be under supervision
by specialist on behavioral disorders in children and / or young people.
Contraindications: Hypersensitivity to the active substance or to any excipient, glaucoma, pheochromocytoma, symptomatic cardiovascular disease, structural heart disease and / or moderate or severe hypertension, heart failure, arterial narrowing, angina, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, cardiac myocardial infarction, potentially life-threatening arrhythmias, and cardiac myocardial infarction (diseases caused by a dysfunction of ion channels) advanced arteriosclerosis, concomitant use of monoamine oxidase inhibitors (MAO inhibitors) or within 14 days of treatment with MAO inhibitors, hyperthyroidism or thyroid toxicosis, severe depression, anorexia nervosa / anorectic disorders, hyperexcitability, suicidal thoughts, psychotic disorders symptoms, severe and episodic (type I) bipolar (affective) disease (not well controlled), schizophrenia, psychopathic / borderline personality disorder, tourette's syndrome or similar dystonias, cerebrovascular disease (cerebral aneurysm, vascular disorders including vasculitis or stroke), porphyria, previous drug or alcohol abuse. Very common side effects: decreased appetite, decreased weight gain and weight loss during prolonged use in children. Common side effects: arrhythmia, palpitations, tachycardia, abdominal pain and seizures, nausea, vomiting, dry mouth, changes in blood pressure and heart rate (usually elevations), arthralgia, vertigo, dyskinesia, headache, hyperactivity, abnormal behavior, aggression, excitation, anorexia, anxiety, anxiety, anxiety, anxiety, anxiety, depression, irritability. For further information see www.fass.se.
Swedish representative Evolan Pharma AB, Box 120, 182 20 Danderyd. Tel. +46 8 544 960 30 www.evolan.se.
An extensive treatment program usually includes psychological, educational and social measures. Diagnosis should be made according to the criteria in the DSM-5 or the guidelines in ICD-10 and should be based on a comprehensive multidisciplinary evaluation of the patient.
Dexamfetamine is indicated as part of a comprehensive treatment program for Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years when response to previous methylphenidate treatment is considered clinically inadequate. A comprehensive treatment program typically includes psychological, educational and social measures.
Diagnosis should be made according to DSM-5 criteria or the guidelines in ICD-10 and should be based on a comprehensive multidisciplinary evaluation of the patient.